NASDAQ:JUNO - Juno Therapeutics Stock Price, Price Target & More

$86.96 +0.09 (+0.10 %)
(As of 04/19/2018 03:42 PM ET)
Previous Close$86.87
Today's Range$86.90 - $87.01
52-Week Range$19.62 - $87.01
Volume3.70 million shs
Average Volume5.48 million shs
Market Capitalization$9.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.24

About Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO News and Ratings via Email

Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:JUNO
CUSIPN/A
Phone+1-206-5821600

Debt

Debt-to-Equity Ratio0.01%
Current Ratio3.61%
Quick Ratio4.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$111.87 million
Price / Sales90.26
Cash FlowN/A
Price / CashN/A
Book Value$10.18 per share
Price / Book8.54

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-245,580,000.00
Net Margins-390.66%
Return on Equity-39.24%
Return on Assets-29.31%

Miscellaneous

Employees553
Outstanding Shares116,110,000

How to Become a New Pot Stock Millionaire

Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) announced its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.80) by $0.07. The biopharmaceutical company earned $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative net margin of 390.66% and a negative return on equity of 39.24%. The firm's revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.57) earnings per share. View Juno Therapeutics' Earnings History.

What price target have analysts set for JUNO?

17 brokers have issued 1 year price targets for Juno Therapeutics' stock. Their predictions range from $23.73 to $87.00. On average, they expect Juno Therapeutics' stock price to reach $56.21 in the next twelve months. View Analyst Ratings for Juno Therapeutics.

What are Wall Street analysts saying about Juno Therapeutics stock?

Here are some recent quotes from research analysts about Juno Therapeutics stock:
  • 1. According to Zacks Investment Research, "Juno remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging. Moreover, the company’s targeted, cancer immunotherapy is a highly lucrative area as these therapies have the potential to change the treatment paradigm for cancer. Shares of the company have also outperformed the industry in the last one year. However, the company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock." (2/21/2018)
  • 2. Maxim Group analysts commented, "The American Society of Hematology (ASH) is now over, and while we saw bluebird’s (BLUE – $190.95 – Hold) valuation rise to over $9B on strong data in CAR-T and gene therapy, Juno’s valuation has seen a retracement from its pre- ASH peak of $7B, to $5B on what is incremental data for lead CAR candidate JCAR017." (12/13/2017)

Who are some of Juno Therapeutics' key competitors?

Who are Juno Therapeutics' key executives?

Juno Therapeutics' management team includes the folowing people:
  • Howard H. Pien, Independent Chairman of the Board (Age 59)
  • Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)
  • Sunil Agarwal M.D., President of Research & Development (Age 47)
  • Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
  • Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
  • Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
  • Ann Lee Ph.D., Executive Vice President - Technical Operations
  • Patrick Y. Yang, Executive Vice President (Age 69)
  • Cynthia Elkins, Chief Information Officer
  • Bernard J. Cassidy, General Counsel, Secretary (Age 62)

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an initial public offering on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

Has Juno Therapeutics been receiving favorable news coverage?

Headlines about JUNO stock have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Juno Therapeutics earned a coverage optimism score of 0.23 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Juno Therapeutics' major shareholders?

Juno Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include CELGENE CORP (85.40%), CELGENE CORP (85.40%) and CELGENE CORP (9.70%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Jay T Flatley, Richard Klausner, Robert Azelby, Steve Harr and Sunil Agarwal. View Institutional Ownership Trends for Juno Therapeutics.

How do I buy shares of Juno Therapeutics?

Shares of JUNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juno Therapeutics' stock price today?

One share of JUNO stock can currently be purchased for approximately $86.96.

How big of a company is Juno Therapeutics?

Juno Therapeutics has a market capitalization of $9.93 billion and generates $111.87 million in revenue each year. Juno Therapeutics employs 553 workers across the globe.

How can I contact Juno Therapeutics?

Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600.


MarketBeat Community Rating for Juno Therapeutics (JUNO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  614
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe JUNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JUNO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Juno Therapeutics (NASDAQ:JUNO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
17 Wall Street analysts have issued ratings and price targets for Juno Therapeutics in the last 12 months. Their average twelve-month price target is $56.21, suggesting that the stock has a possible downside of 35.36%. The high price target for JUNO is $87.00 and the low price target for JUNO is $23.73. There are currently 15 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.122.122.312.47
Ratings Breakdown: 0 Sell Rating(s)
15 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
15 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.21$56.21$49.9093$39.1236
Price Target Upside: 35.36% downside34.53% downside27.93% downside10.29% downside

Juno Therapeutics (NASDAQ:JUNO) Consensus Price Target History

Price Target History for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Standpoint ResearchReiterated RatingBuy -> HoldLowView Rating Details
1/24/2018BarclaysDowngradeOverweight -> Equal Weight$55.00 -> $87.00LowView Rating Details
1/23/2018Leerink SwannDowngradeOutperform -> Market Perform$56.00 -> $87.00LowView Rating Details
1/23/2018Raymond JamesDowngradeOutperform -> HoldLowView Rating Details
1/22/2018SunTrust BanksReiterated RatingBuy -> HoldLowView Rating Details
1/22/2018Needham & Company LLCDowngradeBuy -> HoldLowView Rating Details
1/22/2018GuggenheimDowngradeBuy -> NeutralLowView Rating Details
1/17/2018CitigroupDowngradeBuy -> NeutralHighView Rating Details
1/17/2018WedbushDowngradeOutperform -> NeutralHighView Rating Details
1/17/2018Wells FargoReiterated RatingMarket Perform$54.00 -> $63.00HighView Rating Details
1/11/2018JPMorgan ChaseReiterated RatingHoldHighView Rating Details
12/13/2017Maxim GroupSet Price TargetBuy$56.00HighView Rating Details
11/3/2017CowenReiterated RatingBuyN/AView Rating Details
10/6/2017Goldman SachsReiterated RatingNeutral -> Neutral$44.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 -> $43.00N/AView Rating Details
8/28/2017BTIG ResearchUpgradeSell -> NeutralHighView Rating Details
5/18/2017FBR & CoReiterated RatingHoldMediumView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Juno Therapeutics (NASDAQ:JUNO) Earnings History and Estimates Chart

Earnings by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) Earnings Estimates

2018 EPS Consensus Estimate: ($4.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.00)($1.00)($1.00)
Q2 20181($0.97)($0.97)($0.97)
Q3 20181($0.99)($0.99)($0.99)
Q4 20181($1.09)($1.09)($1.09)

Juno Therapeutics (NASDAQ JUNO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.80)($0.73)$18.12 million$44.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.72)($0.96)$15.59 million$21.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.70)($0.71)$16.00 million$19.30 millionViewListenView Earnings Details
3/1/2017Q416($0.61)($0.65)$14.57 million$21.15 millionViewListenView Earnings Details
11/9/2016Q316($0.52)($0.57)$10.98 million$20.80 millionViewListenView Earnings Details
8/4/2016Q216($0.41)($0.64)$14.26 million$27.60 millionViewListenView Earnings Details
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details
2/29/2016Q415($0.54)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details
3/18/2015Q414($0.33)($1.73)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Juno Therapeutics (NASDAQ:JUNO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Juno Therapeutics (NASDAQ JUNO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.08%
Institutional Ownership Percentage: 70.19%
Insider Trading History for Juno Therapeutics (NASDAQ:JUNO)
Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ JUNO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2018Robert AzelbyEVPSell4,157$85.55$355,631.3589,614View SEC Filing  
2/8/2018Robert AzelbyEVPSell3,497$85.77$299,937.6993,771View SEC Filing  
2/1/2018Robert AzelbyEVPSell4,167$85.78$357,445.2696,471View SEC Filing  
1/22/2018Robert AzelbyEVPSell102,539$86.25$8,843,988.75173,371View SEC Filing  
1/17/2018Robert AzelbyEVPSell29,131$68.61$1,998,677.9173,330View SEC Filing  
1/16/2018Hans Edgar BishopCEOSell270,250$46.17$12,477,442.502,772,679View SEC Filing  
1/8/2018Richard KlausnerDirectorSell12,724$48.21$613,424.04741,499View SEC Filing  
12/21/2017Richard KlausnerDirectorSell36,000$44.76$1,611,360.00744,392View SEC Filing  
12/21/2017Steve HarrCFOSell8,750$44.76$391,650.00772,082View SEC Filing  
12/18/2017Robert AzelbyEVPSell1,816$44.96$81,647.3670,832View SEC Filing  
11/2/2017Robert AzelbyEVPSell6,666$54.95$366,296.7079,998View SEC Filing  
10/2/2017Sunil AgarwalInsiderSell7,285$44.76$326,076.60View SEC Filing  
9/14/2017Bernard J CassidyGeneral CounselSell28,000$44.92$1,257,760.0055,970View SEC Filing  
9/13/2017Robert AzelbyEVPSell12,850$44.95$577,607.5037,439View SEC Filing  
9/7/2017Richard KlausnerDirectorSell12,000$42.66$511,920.00783,536View SEC Filing  
8/29/2017Robert AzelbyEVPSell12,869$39.95$514,116.5550,289View SEC Filing  
8/7/2017Richard KlausnerDirectorSell12,000$30.34$364,080.00788,985View SEC Filing  
7/13/2017Douglas K BrattonMajor ShareholderSell8,000,000$27.00$216,000,000.00View SEC Filing  
7/7/2017Richard KlausnerDirectorSell24,000$29.39$705,360.00824,985View SEC Filing  
7/3/2017Steve HarrCFOSell8,750$30.00$262,500.00736,189View SEC Filing  
6/27/2017Steve HarrCFOSell8,750$30.00$262,500.00736,189View SEC Filing  
6/20/2017Anthony B EvninDirectorBuy9,000$24.40$219,600.0066,301View SEC Filing  
5/30/2017Jay T FlatleyDirectorBuy10,000$22.92$229,200.00View SEC Filing  
5/26/2017Jay T FlatleyDirectorBuy20,000$24.76$495,200.00View SEC Filing  
3/10/2017Anthony B EvninDirectorBuy8,000$22.11$176,880.0056,990View SEC Filing  
11/10/2016Robert AzelbyEVPSell12,921$24.14$311,912.9448,640View SEC Filing  
9/27/2016Hans Edgar BishopCEOSell44,000$33.00$1,452,000.002,490,859View SEC Filing  
9/21/2016Hans Edgar BishopCEOSell84,035$30.28$2,544,579.802,518,537View SEC Filing  
9/8/2016Hans Edgar BishopCEOSell23,042$30.06$692,642.522,541,151View SEC Filing  
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00846,799View SEC Filing  
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86117,000View SEC Filing  
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00716,052View SEC Filing  
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.002,704,609View SEC Filing  
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.4855,511View SEC Filing  
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00858,799View SEC Filing  
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.0057,933View SEC Filing  
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00872,792View SEC Filing  
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.0050,000View SEC Filing  
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00882,499View SEC Filing  
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.0061,865View SEC Filing  
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00730,000View SEC Filing  
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00895,259View SEC Filing  
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00762,987View SEC Filing  
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.0063,683View SEC Filing  
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.0066,883View SEC Filing  
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.0070,083View SEC Filing  
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00765,000View SEC Filing  
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.0071,200View SEC Filing  
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00930,499View SEC Filing  
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.0074,400View SEC Filing  
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00942,499View SEC Filing  
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00950,499View SEC Filing  
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.0077,600View SEC Filing  
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.5089,450View SEC Filing  
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Juno Therapeutics (NASDAQ JUNO) News Headlines

Source:
DateHeadline
Juno Therapeutics (JUNO) Downgraded to "Buy" at BidaskClubJuno Therapeutics (JUNO) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 19 at 1:22 PM
Biotech Watchers Are Starting to Wonder: How Big Is Too Big?Biotech Watchers Are Starting to Wonder: How Big Is Too Big?
www.bloomberg.com - April 18 at 5:37 PM
Juno Therapeutics (JUNO) Lifted to "Buy" at VetrJuno Therapeutics (JUNO) Lifted to "Buy" at Vetr
www.americanbankingnews.com - April 18 at 12:16 PM
The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside PotentialThe Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential
www.baystreet.ca - April 18 at 8:26 AM
Juno Therapeutics Inc (JUNO) Receives Consensus Recommendation of "Hold" from BrokeragesJuno Therapeutics Inc (JUNO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 3:21 AM
Juno Therapeutics (JUNO) Lifted to "Hold" at VetrJuno Therapeutics (JUNO) Lifted to "Hold" at Vetr
www.americanbankingnews.com - April 15 at 9:31 AM
Juno Therapeutics (JUNO) Lowered to Sell at VetrJuno Therapeutics (JUNO) Lowered to Sell at Vetr
www.americanbankingnews.com - April 13 at 10:15 AM
Alexion (ALXN) to Acquire Wilson Therapeutics for $855MAlexion (ALXN) to Acquire Wilson Therapeutics for $855M
finance.yahoo.com - April 12 at 5:27 PM
Juno Therapeutics (JUNO) Upgraded at VetrJuno Therapeutics (JUNO) Upgraded at Vetr
www.americanbankingnews.com - April 10 at 6:40 PM
Juno Therapeutics (JUNO) Raised to "Outperform" at WedbushJuno Therapeutics (JUNO) Raised to "Outperform" at Wedbush
www.americanbankingnews.com - April 9 at 8:06 PM
Juno Therapeutics (JUNO) Upgraded at Raymond James FinancialJuno Therapeutics (JUNO) Upgraded at Raymond James Financial
www.americanbankingnews.com - April 9 at 8:06 PM
Cowen Reiterates "Buy" Rating for Juno Therapeutics (JUNO)Cowen Reiterates "Buy" Rating for Juno Therapeutics (JUNO)
www.americanbankingnews.com - April 4 at 5:52 PM
Juno Therapeutics (JUNO) Buy Rating Reiterated at CitigroupJuno Therapeutics' (JUNO) Buy Rating Reiterated at Citigroup
www.americanbankingnews.com - April 2 at 9:42 PM
CAR T Cell Therapy Market is Expected to Grow at the CAGR of 5.96% During 2017-2025: Credence ResearchCAR T Cell Therapy Market is Expected to Grow at the CAGR of 5.96% During 2017-2025: Credence Research
globenewswire.com - April 2 at 5:18 PM
The Lab Tests Behind Immuno-Oncology: Precise Enough?The Lab Tests Behind Immuno-Oncology: Precise Enough?
www.forbes.com - April 2 at 8:52 AM
Juno Therapeutics (JUNO) Upgraded at SunTrust BanksJuno Therapeutics (JUNO) Upgraded at SunTrust Banks
www.americanbankingnews.com - April 2 at 8:20 AM
Juno Therapeutics (JUNO) Earns Outperform Rating from WedbushJuno Therapeutics (JUNO) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - April 2 at 12:30 AM
Juno Therapeutics (JUNO) Receives "Buy" Rating from Maxim GroupJuno Therapeutics (JUNO) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - April 1 at 11:24 PM
Pomerantz LLP Announces Pendency of Class Action Lawsuit Involving Purchasers ...Pomerantz LLP Announces Pendency of Class Action Lawsuit Involving Purchasers ...
www.prnewswire.com - March 28 at 5:11 PM
Pomerantz LLP Announces Pendency of Class Action Lawsuit Involving Purchasers of Juno Therapeutics, Inc. Common StockPomerantz LLP Announces Pendency of Class Action Lawsuit Involving Purchasers of Juno Therapeutics, Inc. Common Stock
www.bizjournals.com - March 28 at 5:11 PM
Wells Fargo Reiterates Market Perform Rating for Juno Therapeutics (JUNO)Wells Fargo Reiterates Market Perform Rating for Juno Therapeutics (JUNO)
www.americanbankingnews.com - March 27 at 6:16 PM
Juno Therapeutics (JUNO) Cut to "Sell" at Zacks Investment ResearchJuno Therapeutics (JUNO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 27 at 6:16 PM
Juno Therapeutics (JUNO) Stock Rating Reaffirmed by Raymond James FinancialJuno Therapeutics (JUNO) Stock Rating Reaffirmed by Raymond James Financial
www.americanbankingnews.com - March 27 at 4:00 PM
Juno Therapeutics (JUNO) Cut to "Hold" at Needham & Company LLCJuno Therapeutics (JUNO) Cut to "Hold" at Needham & Company LLC
www.americanbankingnews.com - March 27 at 12:41 AM
Juno Therapeutics (JUNO) Lowered to "Hold" at Raymond James FinancialJuno Therapeutics (JUNO) Lowered to "Hold" at Raymond James Financial
www.americanbankingnews.com - March 27 at 12:06 AM
Juno Therapeutics (JUNO) Downgraded by BidaskClubJuno Therapeutics (JUNO) Downgraded by BidaskClub
www.americanbankingnews.com - March 25 at 12:16 AM
Parents’ lawsuit claims Celgene unit used child as ‘guinea pig’ in phase II drug trialParents’ lawsuit claims Celgene unit used child as ‘guinea pig’ in phase II drug trial
www.reuters.com - March 24 at 8:59 AM
Juno Therapeutics Inc (JUNO) Given Average Rating of "Hold" by AnalystsJuno Therapeutics Inc (JUNO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 24 at 7:44 AM
Two Really Big Fish That Got AwayTwo Really Big Fish That Got Away
finance.yahoo.com - March 23 at 8:30 AM
Comparing Juno Therapeutics (JUNO) & Shire-Nps Pharmaceuticals (NPSP)Comparing Juno Therapeutics (JUNO) & Shire-Nps Pharmaceuticals (NPSP)
www.americanbankingnews.com - March 18 at 7:26 PM
Contrasting Stemline Therapeutics (STML) & Juno Therapeutics (JUNO)Contrasting Stemline Therapeutics (STML) & Juno Therapeutics (JUNO)
www.americanbankingnews.com - March 14 at 1:26 AM
Form 4 Juno Therapeutics, Inc. For: Mar 05 Filed by: EVNIN ANTHONY B - StreetInsider.comForm 4 Juno Therapeutics, Inc. For: Mar 05 Filed by: EVNIN ANTHONY B - StreetInsider.com
www.streetinsider.com - March 8 at 8:34 AM
Form S-8 POS Juno Therapeutics, Inc.Form S-8 POS Juno Therapeutics, Inc.
www.streetinsider.com - March 7 at 6:23 PM
Editas Medicine Delivers Another Strong QuarterEditas Medicine Delivers Another Strong Quarter
finance.yahoo.com - March 7 at 6:23 PM
Form S-8 POS Juno Therapeutics, Inc. - StreetInsider.comForm S-8 POS Juno Therapeutics, Inc. - StreetInsider.com
www.streetinsider.com - March 7 at 8:29 AM
BRIEF-Celgene Announces Expiration Of Cash Tender Offer For Shares Of Juno Therapeutics - ReutersBRIEF-Celgene Announces Expiration Of Cash Tender Offer For Shares Of Juno Therapeutics - Reuters
www.reuters.com - March 6 at 8:26 AM
Celgene Announces Expiration of Cash Tender Offer for Shares of ... - Business Wire (press release)Celgene Announces Expiration of Cash Tender Offer for Shares of ... - Business Wire (press release)
www.businesswire.com - March 6 at 8:26 AM
Celgene (CELG) Completes Acquisition of Juno Therapeutics (JUNO) - StreetInsider.comCelgene (CELG) Completes Acquisition of Juno Therapeutics (JUNO) - StreetInsider.com
www.streetinsider.com - March 6 at 8:26 AM
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy - Business Wire (press release)Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy - Business Wire (press release)
www.businesswire.com - March 6 at 8:26 AM
Juno Therapeutics Inc (JUNO) Holdings Boosted by Teacher Retirement System of TexasJuno Therapeutics Inc (JUNO) Holdings Boosted by Teacher Retirement System of Texas
www.americanbankingnews.com - March 2 at 7:01 PM
Juno Therapeutics Inc (JUNO) Given Average Recommendation of "Hold" by BrokeragesJuno Therapeutics Inc (JUNO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 27 at 5:28 AM
Juno Therapeutics Inc (JUNO) Holdings Lifted by Swiss National BankJuno Therapeutics Inc (JUNO) Holdings Lifted by Swiss National Bank
www.americanbankingnews.com - February 26 at 8:20 AM
ARK Investment Management LLC Buys 161,380 Shares of Juno Therapeutics Inc (JUNO)ARK Investment Management LLC Buys 161,380 Shares of Juno Therapeutics Inc (JUNO)
www.americanbankingnews.com - February 26 at 5:12 AM
Form SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc. - StreetInsider.comForm SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc. - StreetInsider.com
www.streetinsider.com - February 23 at 8:35 AM
Celgene Gets Antitrust Clearance For Juno Therapeutics Acquisition ... - NasdaqCelgene Gets Antitrust Clearance For Juno Therapeutics Acquisition ... - Nasdaq
www.nasdaq.com - February 23 at 8:35 AM
Blog Exposure - Celgene Gets Antitrust Clearance for Juno’s AcquisitionBlog Exposure - Celgene Gets Antitrust Clearance for Juno’s Acquisition
finance.yahoo.com - February 23 at 8:35 AM
Form SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc.Form SC 14D9/A Juno Therapeutics, Inc. Filed by: Juno Therapeutics, Inc.
www.streetinsider.com - February 22 at 8:30 AM
Juno Therapeutics (JUNO) Raised to "Hold" at Zacks Investment ResearchJuno Therapeutics (JUNO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 21 at 2:11 PM
Celgene Gets Antitrust Clearance For Juno Therapeutics AcquisitionCelgene Gets Antitrust Clearance For Juno Therapeutics Acquisition
www.nasdaq.com - February 21 at 8:31 AM
Celgene Receives Antitrust Clearance for Juno AcquisitionCelgene Receives Antitrust Clearance for Juno Acquisition
finance.yahoo.com - February 21 at 8:31 AM

SEC Filings

Juno Therapeutics (NASDAQ:JUNO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Juno Therapeutics (NASDAQ:JUNO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Juno Therapeutics (NASDAQ JUNO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.